<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847312</url>
  </required_header>
  <id_info>
    <org_study_id>Prograin3</org_study_id>
    <nct_id>NCT02847312</nct_id>
  </id_info>
  <brief_title>Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure</brief_title>
  <official_title>Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PepsiCo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rothamsted Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotechnology and Biological Sciences Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proposed human trial, the investigators aim to establish whether 4 weeks of daily
      consumption of beta-glucan matched meals providing either a high dose or a moderate dose of
      oat avenanthramides and phenolic acids leads to dose-dependent chronic improvements in
      markers of CVD risk and gut health relative to an energy matched control intervention in
      healthy adults with above average blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To investigate the chronic effects of daily intake of oat products on flow mediated
           dilatation of the brachial artery (FMD; primary endpoint), microvascular endothelial
           function (measured by laser Doppler iontophoresis), pulse wave analysis, gut microbiota
           diversity, 24h blood pressure, activity of the renin angiotensin system, markers related
           to cellular production of nitric oxide and reactive oxygen species, inflammatory
           cytokines, and further potentially emerging biochemical markers of CVD risk.

        -  To establish if phenolic acids and avenanthramides from oat products exert
           cardiovascular and microbial effects in a dose dependent manner.

        -  To measure urinary and fecal excretion of avenanthramide and phenolic acid metabolites.

      To explore correlations between bacterial population changes and CVD risk markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilatation</measure>
    <time_frame>20 weeks</time_frame>
    <description>Technique to assess the flexibility of teh endothelium in larger peripheral blood vessels, magnitude of increase in percentage from baseline to after 4 weeks treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laser Doppler Iontophoresis</measure>
    <time_frame>20 weeks</time_frame>
    <description>Magnitude of increase from Baseline to 4weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota changes</measure>
    <time_frame>22 weeks</time_frame>
    <description>Gut microbiota diversity and relative abduance change from Baseline to 4weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma nitric oxide analysis</measure>
    <time_frame>22 weeks</time_frame>
    <description>Concentration of nitric oxide in nmol from Baseline to 4weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NADPH oxidase activity in neutrophil blood cells</measure>
    <time_frame>22 weeks</time_frame>
    <description>NADPH oxidase activity will be calculated as the difference between values obtained in PMA from Baseline to 4weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>22 weeks</time_frame>
    <description>Inflammatory marker levels change from Baseline to 4weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin activity</measure>
    <time_frame>22 weeks</time_frame>
    <description>Renin activity in ng/(mL*hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma microparticles</measure>
    <time_frame>22 weeks</time_frame>
    <description>Microparticles in counts/uL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine and plasma metabolomic footprint using NMR</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>22 weeks</time_frame>
    <description>Glucose concentration in mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma insulin</measure>
    <time_frame>22 weeks</time_frame>
    <description>Insulin concentration in uU/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipids</measure>
    <time_frame>22 weeks</time_frame>
    <description>Plasma lipid concentration in mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Faecal water metabolites</measure>
    <time_frame>22 weeks</time_frame>
    <description>Metabolites in mikrogram/L</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High avenanthramide, phenolic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>66.8g Pepsico Oatmeal + 60g Oat cake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low avenanthramide, medium phenolic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High avenanthramide, phenolic acid</intervention_name>
    <description>High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.</description>
    <arm_group_label>High avenanthramide, phenolic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low avenanthramide, medium phenolic acid</intervention_name>
    <description>Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.</description>
    <arm_group_label>Low avenanthramide, medium phenolic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control are matched with energy and insoluable fibre.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above average blood pressure (i.e. systolic 120-159 mmHg and diastolic 75-99 mmHg)

        Exclusion Criteria:

          -  Abnormal biochemical, haematological results as assessed at health screening

          -  Hypertension (i.e. SBP/DBP ≥160/100 mm Hg)

          -  BMI &gt;35

          -  Current smoker or ex-smoker ceasing &lt;3 months ago

          -  Past or existing medical history of vascular disease, diabetes, hepatic, renal,
             haematological, neurological, thyroidal disease or cancer

          -  Prescribed or taking lipid lowering, antihypertensive, vasoactive (e.g. Viagra),
             anti-inflammatory, antibiotic or antidepressant medication

          -  Allergies to whole grains

          -  Parallel participation in another research project

          -  Having flu vaccination or antibiotics within 3 months of trial start

          -  Chronic constipation, diarrhea or other chronic gastrointestinal complaint

          -  On a weight reduction regime or taking food, probiotics or prebiotics supplements or
             laxative within 3 months of trial start

          -  Performing high level of physical activity (i.e. ≥150min aerobic exercise/week)

          -  Consumption of ≥21 units of alcohol/week

          -  Females who are breast-feeding, may be pregnant, lactating or, if of reproductive age
             and not using a reliable form of contraception (including abstinence)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy P Spencer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Reading</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy P Spencer, Professor</last_name>
    <phone>+44 (0) 118 378 8724</phone>
    <phone_ext>8724</phone_ext>
    <email>j.p.e.spencer@rdg.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Y Schar, PDRA</last_name>
    <phone>+44 (0) 1183786394</phone>
    <email>m.y.schar@reading.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hugh Sinclair Unit of Human Nutrition</name>
      <address>
        <city>Reading</city>
        <zip>RG66AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Weech, Mananger</last_name>
      <phone>01183787771</phone>
      <email>m.weech@reading.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Angelika Kristek, Assistant</last_name>
      <phone>0118378771</phone>
      <email>a.kristek@reading.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel Y Schar, PDRA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy P Spencer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Jeremy Paul Edward Spencer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Oat</keyword>
  <keyword>Phenolic acid</keyword>
  <keyword>Avenanthramide</keyword>
  <keyword>FMD</keyword>
  <keyword>LDI</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Renin Angiotensin</keyword>
  <keyword>Nitric Oxide</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publish</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

